Log in to save to my catalogue

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_741a0ed9af8348169ec0d113889d5597

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

About this item

Full title

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

Publisher

United States: U.S. National Center for Infectious Diseases

Journal title

Emerging infectious diseases, 2025-03, Vol.31 (3), p.467-476

Language

English

Formats

Publication information

Publisher

United States: U.S. National Center for Infectious Diseases

More information

Scope and Contents

Contents

A previous study demonstrated noninferior efficacy of 4-month rifapentine/moxifloxacin regimen for tuberculosis (TB) treatment compared with the standard regimen. We explored results among study participants with diabetes. Among 2,516 randomized participants, 181 (7.2%) had diabetes. Of 166 participants with diabetes in the microbiologically eligib...

Alternative Titles

Full title

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_741a0ed9af8348169ec0d113889d5597

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_741a0ed9af8348169ec0d113889d5597

Other Identifiers

ISSN

1080-6040,1080-6059

E-ISSN

1080-6059

DOI

10.3201/eid3103.241634

How to access this item